Common Stock, par value $0.01 per share
- Symbol
- INSM
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Insmed Incorporated
INSMNASDAQEQUITYCurrent
Results of Operations and Financial Condition
ITEM 2.02 Results of Operations and Financial Condition. On October 29, 2026, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02.…
Press release in this filing
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update →Company context
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines - including two approved therapies to treat chronic, debilitating lung diseases - as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Current securities
Recent company filings
- 10-Q filingOct 29, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 20, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 5, 2026
- 4 filingSep 11, 2026
- 144 filingSep 10, 2026
Registered securities in this filing
INSMED INCORPORATED · 8-K · Filed 2026-10-29
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
ITEM 2.02 Results of Operations and Financial Condition.
On October 29, 2026, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the third quarter ended September 30,
2026. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02. The slide presentation to be used during the conference call referenced in the press release is attached hereto as Exhibit 99.2 and incorporated
herein by reference.
The information contained herein, including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (2)
Exhibit 99.1 Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update - Total Company Revenues of $524.4 Million for the Third Quarter of 2026 - - BRINSUPRI® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of 2026 - - ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $124.4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of 2025 - - Company Raises 2026 BRINSUPRI Revenue Guidance to $1.35 Billion to $1.4 Billion - - Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million - - Insmed Launches BRINSUPRI Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan - BRIDGEWATER, N.J., October 29, 2026 - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “The third quarter marked another period of meaningful progress, de…
Open exhibit ↗Exhibit 99.2 October 29, 2026 Third-Quarter 2026 Earnings Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: failure to continue to successfully commercialize ARIKAYCE® in the U.S., Europe or Japan or failure to successfully commercialize BRINSUPRI® in the U.S. or Japan, or to maintain U.S., European or Japanese approval for ARIKAYCE or U.S., European or Japanese approval for BRINSUPRI; our inability to obtain full approval of ARIKAYCE from the FDA or our failure to obtain regulatory approval to expand ARIKAYCE’s indication to a broader patient population; failure to obtain, or delays in obtaining, regulatory approvals for our product candidates in the U.S., Europe o…
Open exhibit ↗